Lactobacillus Mucosae Strain Promoted by a High-Fiber Diet in Genetic Obese Child Alleviates Lipid Metabolism and Modifies Gut Microbiota in ApoE-/- Mice on a Western Diet

Abstract

Supplementation of probiotics is a promising gut microbiota-targeted therapeutic method for hyperlipidemia and atherosclerosis. However, the selection of probiotic candidate strains is still empirical. Here, we obtained a human-derived strain, Lactobacillus mucosae A1, which was shown by metagenomic analysis to be promoted by a high-fiber diet and associated with the amelioration of host hyperlipidemia, and validated its effect on treating hyperlipidemia and atherosclerosis as well as changing structure of gut microbiota in ApoE-/- mice on a Western diet. L. mucosae A1 attenuated the severe lipid accumulation in serum, liver and aortic sinus of ApoE-/- mice on a Western diet, while it also reduced the serum lipopolysaccharide-binding protein content of mice, reflecting the improved metabolic endotoxemia. In addition, L. mucosae A1 shifted the gut microbiota structure of ApoE-/- mice on a Western diet, including recovering a few members of gut microbiota enhanced by the Western diet. This study not only suggests the potential of L. mucosae A1 to be a probiotic in the treatment of hyperlipidemia and atherosclerosis, but also highlights the advantage of such function-based rather than taxonomy-based strategies for the selection of candidate strains for the next generation probiotics.

Maternal Gut Dysbiosis Alters Offspring Microbiota and Social Interactions

“…However, perturbations of gut microbiota of adult mothers failed to significantly impair their sociability and preference for social novelty. These observations suggest that alterations in the gut microbiota during the critical early developmental periods have been associated with changed behavioral phenotypes in our mice and other mouse models [ 48 , 49 , 50 ].…”

Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke

“…In comparison to pharmaceutical agents, nutraceuticals generated from the food after fermentation by probiotic bacteria have evoked greater interest in atherosclerosis prevention [ 90 ]. Supplementation of probiotic L. mucosae A1 exhibited effectiveness in the treatment of hyperlipidemia and atherosclerosis and improved gut microbiota dysbiosis, including increased richness and diversity in ApoE -/- mice on a Western diet [ 91 ]. The anti-atherosclerotic effects of L. plantarum ATCC 14917 were also observed in ApoE -/- mice via modulation of proinflammatory cytokines TNFα and IL1-β, oxidative stress, and gut microbiota [ 92 ].…”

Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota

“…In vitro studies showed the cholesterol-lowering effect of strains with BSH activity, including L. alimentarius, L. paraplantarum, and L. pentosus (189)(190)(191). Lactobacillus supplementation with L. buchneri, L. johnsonii, and L. mucosae decreased serum cholesterol levels to prevent hypercholesterolemia (77,(192)(193)(194)(195). Specifically, L. johnsonii BS15 markedly enhanced the population of Bacteroidetes and Lactobacillus spp.…”